200 related articles for article (PubMed ID: 6178607)
1. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response.
Maryanski JL; Van Snick J; Cerottini JC; Boon T
Eur J Immunol; 1982 May; 12(5):401-6. PubMed ID: 6178607
[TBL] [Abstract][Full Text] [Related]
2. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones.
Maryanski JL; Boon T
Eur J Immunol; 1982 May; 12(5):406-12. PubMed ID: 6178608
[TBL] [Abstract][Full Text] [Related]
3. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
4. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. V. H-2 associativity of variant-specific antigens.
Van Snick J; Maryanski J; Van Pel A; Parmiani G; Boon T
Eur J Immunol; 1982 Nov; 12(11):905-8. PubMed ID: 6818041
[TBL] [Abstract][Full Text] [Related]
5. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815.
Brichard VG; Warnier G; Van Pel A; Morlighem G; Lucas S; Boon T
Eur J Immunol; 1995 Mar; 25(3):664-71. PubMed ID: 7705394
[TBL] [Abstract][Full Text] [Related]
6. H2-restricted recognition of cloned HLA class I gene products expressed in mouse cells.
Maryanski JL; Accolla RS; Jordan B
J Immunol; 1986 Jun; 136(12):4340-7. PubMed ID: 3086429
[TBL] [Abstract][Full Text] [Related]
7. Tumour cell variants with increased immunogenicity obtained by mutagen treatment.
Boon T; Maryanski J
Cancer Surv; 1985; 4(1):135-48. PubMed ID: 3879855
[TBL] [Abstract][Full Text] [Related]
8. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.
Uyttenhove C; Maryanski J; Boon T
J Exp Med; 1983 Mar; 157(3):1040-52. PubMed ID: 6187879
[TBL] [Abstract][Full Text] [Related]
9. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. I. Preferential reactivity of in vitro generated secondary CTL with syngeneic tumor cells.
Plata F; Jongeneel V; Cerottini JC; Brunner KT
Eur J Immunol; 1976 Nov; 6(11):823-9. PubMed ID: 187429
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1.
Inge TH; Hoover SK; Susskind BM; Barrett SK; Bear HD
Cancer Res; 1992 Mar; 52(6):1386-92. PubMed ID: 1531782
[TBL] [Abstract][Full Text] [Related]
11. Specific reversal of cytolytic T cell-target cell functional binding is induced by free target cells.
Balk SP; Mescher MF
J Immunol; 1981 Jul; 127(1):51-7. PubMed ID: 6787131
[TBL] [Abstract][Full Text] [Related]
12. Degradation of specificity in cytolytic T lymphocyte clones: two broad specificity, H-2-independent recognition systems, one natural killer-like, develop during culture, in addition to the clonally distributed antigen-specific receptor.
Wilson A; Shortman K
Eur J Immunol; 1985 Sep; 15(9):899-905. PubMed ID: 2412835
[TBL] [Abstract][Full Text] [Related]
13. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants.
Maryanski JL; Marchand M; Uyttenhove C; Boon T
Int J Cancer; 1983 Jan; 31(1):119-23. PubMed ID: 6187698
[TBL] [Abstract][Full Text] [Related]
14. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.
Boon T; Van Snick J; Van Pel A; Uyttenhove C; Marchand M
J Exp Med; 1980 Nov; 152(5):1184-93. PubMed ID: 6776227
[TBL] [Abstract][Full Text] [Related]
15. Degradation of specificity in cytolytic T lymphocyte clones. The separate YAC-1-type (NK-like) and P815-type broad specificity killing patterns are both restricted to the larger cells within a clone but may be expressed independently in clones from different mouse strains.
Shortman K; Wilson A
J Immunol; 1986 Aug; 137(3):798-804. PubMed ID: 2424983
[TBL] [Abstract][Full Text] [Related]
16. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VII. Dominant expression of variant antigens in somatic cell hybrids.
Maryanski JL; Szpirer J; Szpirer C; Boon T
Somatic Cell Genet; 1983 May; 9(3):345-57. PubMed ID: 6407125
[TBL] [Abstract][Full Text] [Related]
17. Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice.
Germain RN; Williams RM; Benacerraf B
Am J Pathol; 1976 Dec; 85(3):661-74. PubMed ID: 826167
[TBL] [Abstract][Full Text] [Related]
18. Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815.
Bilsborough J; Van Pel A; Uyttenhove C; Boon T; Van den Eynde BJ
J Immunol; 1999 Mar; 162(6):3534-40. PubMed ID: 10092811
[TBL] [Abstract][Full Text] [Related]
19. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. II. Analysis of the clonal progeny of CTL precursors stimulated in vitro with syngeneic tumor cells.
Brunner KT; MacDonald HR; Cerottini JC
J Immunol; 1980 Apr; 124(4):1627-34. PubMed ID: 6154076
[No Abstract] [Full Text] [Related]
20. Human cytotoxic T lymphocytes. III. Large numbers of peripheral blood T cells clonally develop into allorestricted anti-viral cytotoxic T cell populations in vitro.
Kabelitz D; Herzog WR; Heeg K; Wagner H; Reimann J
J Mol Cell Immunol; 1987; 3(1):49-60. PubMed ID: 2855406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
